CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Update

CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 3,620 shares, a decline of 43.2% from the August 31st total of 6,370 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 11,046 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

GDTC has been the subject of several recent analyst reports. Fundamental Research set a $4.16 target price on CytoMed Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.16.

Get CytoMed Therapeutics alerts:

Read Our Latest Research Report on CytoMed Therapeutics

CytoMed Therapeutics Stock Down 5.2%

GDTC stock traded down $0.05 during midday trading on Wednesday, reaching $0.84. 13,004 shares of the company were exchanged, compared to its average volume of 13,804. The stock’s 50-day simple moving average is $0.90 and its 200 day simple moving average is $0.98. CytoMed Therapeutics has a 1-year low of $0.68 and a 1-year high of $3.68. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.06.

CytoMed Therapeutics (NASDAQ:GDTC – Get Free Report) last released its quarterly earnings data on Wednesday, September 30th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million for the quarter.

About CytoMed Therapeutics

(Get Free Report)

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms.

Read More

• Five stocks we like better than CytoMed Therapeutics
• Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
• O’Reilly Automotive’s Stock Slump Hides a Stronger Business
• McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
• Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test

Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.